KR100869868B1 - 국부 지방축적과 셀룰라이트의 치료를 위한 약제 및/또는화장품 조성물 - Google Patents
국부 지방축적과 셀룰라이트의 치료를 위한 약제 및/또는화장품 조성물 Download PDFInfo
- Publication number
- KR100869868B1 KR100869868B1 KR1020037015485A KR20037015485A KR100869868B1 KR 100869868 B1 KR100869868 B1 KR 100869868B1 KR 1020037015485 A KR1020037015485 A KR 1020037015485A KR 20037015485 A KR20037015485 A KR 20037015485A KR 100869868 B1 KR100869868 B1 KR 100869868B1
- Authority
- KR
- South Korea
- Prior art keywords
- phospholipids
- complex
- cellulite
- derived
- escin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 208000035484 Cellulite Diseases 0.000 title claims abstract description 13
- 206010049752 Peau d'orange Diseases 0.000 title claims abstract description 13
- 230000036232 cellulite Effects 0.000 title claims abstract description 13
- 239000002537 cosmetic Substances 0.000 title claims abstract description 13
- 208000023184 Body fat disease Diseases 0.000 title description 2
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 29
- 229940011399 escin Drugs 0.000 claims abstract description 13
- 229930186222 escin Natural products 0.000 claims abstract description 13
- 239000000284 extract Substances 0.000 claims abstract description 13
- 235000021508 Coleus Nutrition 0.000 claims abstract description 12
- 244000061182 Coleus blumei Species 0.000 claims abstract description 12
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 12
- 239000000539 dimer Substances 0.000 claims abstract description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 10
- 229930003935 flavonoid Natural products 0.000 claims abstract description 10
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 10
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 10
- 150000003648 triterpenes Chemical class 0.000 claims abstract description 10
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims abstract description 9
- 229950005143 sitosterol Drugs 0.000 claims abstract description 9
- 229940076810 beta sitosterol Drugs 0.000 claims abstract description 8
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims abstract description 8
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims abstract description 8
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 12
- 244000146462 Centella asiatica Species 0.000 claims description 9
- 235000004032 Centella asiatica Nutrition 0.000 claims description 9
- 238000009825 accumulation Methods 0.000 claims description 7
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 6
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 abstract description 7
- 241000167550 Centella Species 0.000 abstract 1
- 235000011201 Ginkgo Nutrition 0.000 abstract 1
- 235000008100 Ginkgo biloba Nutrition 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 239000003814 drug Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 241000157282 Aesculus Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 230000003501 anti-edematous effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 235000010181 horse chestnut Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- 102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 description 1
- 108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 description 1
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 206010048961 Localised oedema Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000781615 Olax dissitiflora Species 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 229920004482 WACKER® Polymers 0.000 description 1
- 235000006803 Ximenia Nutrition 0.000 description 1
- 241000488894 Ximenia Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 1
- 229940098366 cola extract Drugs 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- JPMIIZHYYWMHDT-UHFFFAOYSA-N octhilinone Chemical compound CCCCCCCCN1SC=CC1=O JPMIIZHYYWMHDT-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
본 발명은 다음의 활성 성분의 화합물을 포함한 약제 및/또는 화장품 조성물에 관한 것으로 : a) 인지질과 에스신(escin)/베타-시토스테롤(beta-sitosterol)의 복합체, b) 인지질과 은행나무(Gingko biloba) 유래 이량체의 플라보노이드류의 복합체, c) 인지질과 센텔라 아시아티카(Centella asiatica) 유래 트리털펜(triterpenes)의 복합체, 그리고 임의의 하나 또는 둘 다로 : d) 에틸 지메니네이트(ethyl ximeninate), e) 콜레우스 폴스콜리(Coleus forskolii) 추출물 중에서 포함한다.
인지질과 에스신(escin)/베타-시토스테롤(beta-sitosterol) 복합체, 지방축적(adiposities), 셀룰라이트(cellulite).
Description
본 발명은 국부 지방축적(lacalised adiposities)과 셀룰라이트(cellulite)의 치료를 위한 약제 및/또는 화장품 조성물에 관한 것이다.
국부 지방축적과 셀룰라이트는 서구 인구, 주로 여성에서 주목할만한, 점점 증가하는 추세에 있다. 특히, 셀룰라이트는 많은 정상적인 체중-체질에 영향을 미치며, 비만 문제없는 성인 여성에게도 역시 영향을 준다. 이들 문제들은 지방층병적(panniculopathy) 상태와 연관이 있으며, 말초 순환부전, 부종, 섬유증과 변형 지방세포 대사물질에 의해 나타나며, 그런 까닭에 이상적인 치료는 모든 이들 요인을 고려하여 수행되어야 한다.
시장에서 일반적으로 이용할 수 있는 국부 지방축적과 셀룰라이트의 치료를 위한 약제 또는 화장품의 많은 제제가 국부 지방축적과 셀룰라이트의 문제를 만족스럽게 해결하지는 못하였다. 언급된 조성물은 일반적으로 담쟁이덩쿨(ivy), 마로니에(horse-chestnut), 콜라(cola) 추출물인 카페인, 베타-아드레날린성의 흥분제, 메틸크산틴(methylxanthines) 등과 같은 식물 기원의 활성 성분에 근거 한 것이다. 그럼에도 불구하고, 언급된 조성물의 어느 것도 이제까지 실제로 효과적임이 증명되지 못했고, 얻어진 결과들은 종종 조성물의 사용에 의한 것보다는 치료와 연관된 일반적인 식이 섭생에 의한 것으로 밝혀졌다.
본 발명의 목적은 식물 기원의 활성 성분들의 조합물을 함유한 약제 및/또는 화장품의 국소적 조성물을 제공하고자 하는 것으로, 항-부종, 항포스포디에스테라제(antiphosphodiesterase), 혈관운동의 활성 작용이 있고, 콜라겐 생산을 촉진시키는 다양한 조성물의 다른 활성의 조합으로 인하여 피부의 지방 퇴적물과 "오렌지 껍질"같은 피부를 과감히 제거하는 국부 지방축적과 셀룰라이트의 치료에서 뛰어난 결과를 준다.
본 발명의 조성물의 성분은 모두 알려져 있고, 제약업 그리고/또는 화장품업에서 사용되는데, 그럼에도 불구하고 따로따로 사용됐을 때, 언급한 단독 성분의 활성도는 본 발명의 조성물에서 달성되는 것 보다 훨씬 낮은데 주목 되었고 ; 이에 반하여, 언급된 다양한 성분들 중에서 상승적 효과가 관찰되었다.
특히, 본 발명은 유효성분으로 인지질과 에스신(escin) / 베타-시토스테롤 (beta-sitosterol) 복합체, 인지질과 은행나무(Gingko biloba) 유래 이량체·플라보노이드류의 복합체, 에틸 지메니네이트(ethyl ximeninate), 콜레우스 폴스콜리 (Coleus forskolii) 추출물과, 인지질과 센텔라 아시아티카(Centella asiatica) 유래 트리털펜(triterpenes)의 복합체를 함유한 약제 및/또는 화장품의 국소조성물을 제공한다.
보다 상세히는, 본 발명은 다음의 활성 성분의 조합물을 함유한 약제 및/또 는 화장품 조성물에 관한 것이다.
a) 인지질과 에스신(escin) / 베타-시토스테롤(beta-sitosterol)의 복합체,
b) 인지질과 은행나무(Gingko biloba) 유래 이량체의 플라보노이드류의 복합체,
c) 인지질과 센텔라 아시아티카(Centella asiatica) 유래 트리털펜(triterpenes) 복합체,
그리고 임의의 하나 또는 둘 다로 :
d) 에틸 지메니네이트(ethyl ximeninate),
e) 표준화된 콜레우스 폴스콜리(Coleus forskolii) 추출물 중에서 포함한다.
본 발명의 바람직한 태양에 따르면, 본 발명의 조성물은 다음의 조성물 백분율을 갖는다 :
a) 인지질과 에스신(escin) / 베타-시토스테롤(beta-sitosterol)의 복합체 :
0.1 - 2.5 % ;
b) 인지질과 은행나무(Gingko biloba) 유래 이량체의 플라보노이드류의 복합체 :
0.1 - 2.5 % ;
c) 인지질과 센텔라 아시아티카(Centella asiatica) 유래 트리털펜(triterpenes)의 복합체 : 0.1 - 2.5 % ,
그리고 임의의 하나 또는 둘 다로 :
d) 에틸 지메니네이트(ethyl ximeninate) : 0.1 - 2.5 % ;
e) 표준화된 콜레우스 폴스콜리(Coleus forskolii) 추출물 : 0.1 - 2.5 %.
에스신(escin)은 마로니에(horse-chestnut) 종자에 함유된 사포닌(saponin) 으로, 대개는 모세관 투과성을 변성시키기 때문에 현저한 항-부종의 특성을 가진다 : 사실 에스신(escin)은 물의 교환으로 인하여, 모세관 벽의 기공의 수와 직경을 축소하는 능력이 있다. 그런 까닭에, 에스신(escin) 특성은 셀룰라이트와 국부 지방축적의 특유의 국부 부종 상태의 치료에 유용한 것으로 사료된다.
인지질과 에스신(escin) / 베타-시토스테롤(beta-sitosterol)의 복합체는 유럽특허 제 0 283 713호에 발표되었고, 에스신(escin)과 동일한 활성을 갖으나, 활성 성분의 보다 많은 량의 지속적 방출을 보여주고 생물학적 이용효능 역시 개선되었다.
인지질과 은행나무(Gingko biloba) 유래 이량체의 플라보노이드류의 복합체는 유럽특허 제 0 275 005호에 발표되었고, 유리형의 은행나무(Gingko biloba) 유래 이량체의 플라본과 같은 활성도를 갖으나, 활성 성분의 보다 많은 량의 지속적 방출과 보다 나은 생물학적 이용효능을 보여준다. 인지질에서 은행나무(Gingko biloba) 이량체의 플라보노이드류는 히스타민과 마스트(mast) 세포 유래 효소인 cAMP 포스포디에스테라제의 방출에 대한 억제 작용으로 인하여 아주 효능 있는 혈관활성 약물이다. 이 효소의 억제 작용은 cAMP의 수치로 증가를 수반하고, 이 물질은 지방세포 물질대사를 활성화 할 수 있는 능력이 있다. 이들 복합체들은 그런 까닭에 지방세포의 작용을 나타내며, 미세혈관의 환류와 피부의 영양성을 개선한다.
센텔라 아시아티카(Centella asiatica) 유래 트리털펜(triterpenes)은 피부의 섬유아세포(fibroblasts)에 의한 콜라겐의 생산(안정한 형태)에 대하여 유익한 작용을 나타내고, 콜라겐 합성을 위한 기본이 되는 하이드록시프롤린 (hydroxyproline)의 흡수를 증가시키고 셀룰라이트의 전형적인"귤-껍질 피부" 의 형성에 원인이되는 피부 경화증과 대조를 이루므로서 유익한 작용을 하는 것이다. 인지질과 센텔라 아시아티카(Centella asiatica) 유래 트리털펜(triterpenes)의 복합체는 유럽특허 제 0 283 713호에, 피부에 대하여 지속적 방출과 보다 나은 침투력을 갖는 것으로 발표되었다.
에틸 지메니네이트(ethyl ximeninate)는 지메니네이트산(ximeninic acid)의 에틸 에스테르로, 올락스 디지티후로라(Olax dissitiflora)에서 발견된 지방산이고, 지메니아(Ximenia) 속의 다른 유질의 식물 중에서도 발견된다. 모세혈관현미경검사법의 개량 기술로 에틸 지메니네이트(ethyl ximeninate)가 특이한 혈관운동의 활성을 가짐이 밝혀졌다. 제형 중 다른 활성 성분의 활성과의 조합으로 셀룰라이트의 치료에 유용하다.
실시예 1에서 설명된, 표준화된 콜레우스 폴스콜리(Coleus forskolii) 추출물은 포스코린(forskolin)을 함유하고, 이는 잘-특성화된 분자물로 아데닐에이트 시클라아제(adenylate cyclase)의 활성을 자극할 수 있고, 그리고 그런 까닭에 미세혈관의 레블에서 지방분해와 혈관 흐름을 자극시키는 분자물인, 환상 뉴클레오티드(cyclic nycleotides)의 농도를 증가시킬 수 있는 능력이 있다.
본 발명의 조성물은 전형적으로 국부 지방축적 및/또는 셀룰라이트에 영향 받은 신체 부위에, 수 일로부터 수 개월 범위의 기간 동안, 치료할 질환의 심각 정도에 따라, 하루 1 - 2 회 주기로 적용될 것이다.
발명의 조성물은 크림(cream), 기름(oil), 폼(foam), 에멀젼(emulsion), 유 제(milk)와 같은, 관용의 기술에 따라, 마음대로 리포솜(liposomes) 중 캡슐로 싸여 조제될 것이다. 언급된 조성물은 약제와 화장품 기술 분야에서 사용된 관용의 부형제를 함유할 것이다.
제제의 실시예를 아래 기재하였다.
실시예 1 - 콜레우스 폴스콜리(Coleus forskolii)의 20 % forskolin 표준화된 추출물의 제조
곱게 갈은, 콜레우스 폴스콜리(Coleus forskolii)의 뿌리줄기(rhizomes)와 뿌리(roots) 1 kg을 45 ℃ 기온과 240 바(bars)의 압력에서 2시간 동안 연속 환류하 CO2 의 101를 사용하여 계속 추출하였다. 50 ℃에서 용매의 증발 후, 잔존물은 헥산(hexane) 5 부피량(volumes)에 용해시키고, 다음 90 % v/v 메탄올(methanol) 2 부피량(volumes)으로 2회 후 추출한다.
메탄올 추출물은 건조로 농축시켜 20 % forskolin을 함유한 추출물 45 g을 획득한다.
실시예 2 - 크림 제형
크림 100g 중 함유 :
인지질과 에스신(escin) / 베타-시토스테롤(beta-sitosterol)의 복합체 1.50 g
인지질과 센텔라 아시아티카(Centella asiatica)유래 트리털펜(triterpenes)의
복합체 0.50 g
인지질과 이량체의 은행나무(Gingko biloba)유래 플라보노이드류의 복합체 0.50 g
콜레우스 폴스콜리(Coleus forskolii)유래 표준화된 추출물(20 % forskolin)0.50 g
에틸 지메니네이트(ethyl ximeninate) 0.50 g
C12-C15 알킬 벤조에이트(alkyl benzoate) (Finsolv TN - Finetex) 7.50 g
시클로메티콘(Cyclomethicon) (Bensil CMO40 - Wacker) 6.00 g
글리세릴 스테아레이트(Glyceryl stearate)와 PEG-100
스테아레이트(stearate) (Arlacel 165 V-ICI) 3.00 g
폴리솔베이트(Polysorbate) 60 (Tween 60 - ICI) 2.00 g
세틸 알코올(Cetyl alcohol) 1.00 g
아보카도 기름(Avocado oil - Jan Dekker) 1.00 g
비타민 E 아세테이트(acetate) 0.20 g
아스코빌 팔미테이트(Ascobyl palmitate) 0.10 g
폴리아크릴아미드(Polyacrylamide) (e) C13-14 이소파라핀(isoparaffin)
(e) 로레스(Laureth)-7 (Sepigel 305 - Seppic) 3.00 g
이미다졸리디닐유리아(Imodazolidinyurea) 0.30 g
메틸클로로이소티아졸리논(Methychloroisothiazolinone) (and)
메틸이소티아졸리논(methyisothiazolinone) (Kathon CG - Rohm & Haas) 0.05 g
비소딕(Bisodic) EDTA 0.10 g
BHT 0.05 g
향료(Perfume) (162 - AGF) 0.20 g
정제수 적량 (총) 100 g
Claims (5)
- 하기와 같이 구성된 국부 지방축적 및 셀룰라이트 개선용 화장품 조성물 :a) 인지질과 에스신(escin) / 베타-시토스테롤(beta-sitosterol)의 복합체,b) 인지질과 은행나무(Gingko biloba)유래 이량체의 플라보노이드류의 복합체,c) 인지질과 센텔라 아시아티카(Centella asiatica) 트리털펜(triterpenes)의 복합체,d) 에틸 지메니네이트(ethyl ximeninate),e) 콜레우스 폴스콜리(Coleus forskolii) 추출물을 함유한다.
- 청구항 1에 있어서, 조성물이 다음 백분율의 조성을 갖는 화장품 조성물 :a) 인지질과 에스신(escin) / 베타-시토스테롤(beta-sitosterol)의 복합체 :0.1 - 2.5 % ;b) 인지질과 은행나무(Gingko biloba) 유래 이량체의 플라보노이드류의 복합체 :0.1 - 2.5 % ;c) 인지질과 센텔라 아시아티카(Centella asiatica) 트리털펜(triterpenes)의 복합 체 : 0.1 - 2.5 % ,d) 에틸 지메니네이트(ethyl ximeninate) : 0.1 - 2.5 % ;e) 콜레우스 폴스콜리(Coleus forskolii) 추출물 : 0.1 - 2.5 % 을 함유한다.
- 청구항 1과 2 중 어느 한 항에 있어서, 조성물이 하기와 같이 구성된 화장품 조성물 :a) 인지질과 에스신(escin) / 베타-시토스테롤(beta-sitosterol)의 복합체 1.50 g,b) 인지질과 센텔라 아시아티카(Centella asiatica) 유래 트리털펜(triterpenes)의복합체 0.50 g,c) 인지질과 이량체의 은행나무(Gingko biloba) 유래 플라보노이드류의 복합체 0.50 gd) 콜레우스 폴스콜리(Coleus forskolii) 추출물(20 % forskolin) 0.50 ge) 에틸 지메니네이트(ethyl ximeninate) 0.50 g
- 청구항 1과 2 중 어느 한 항에 있어서, 콜레우스 폴스콜리(Coleus forskolii)의 추출물은 20 % 포스코린(forskolin)을 함유한 추출물인 화장품 조성물.
- 삭제
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2001MI001182A ITMI20011182A1 (it) | 2001-06-05 | 2001-06-05 | Composizioni farmaceutiche e/o cosmetiche per il trattamento di adiposita' localizzate e della cellulite |
ITMI01A001182 | 2001-06-05 | ||
PCT/EP2002/005390 WO2002098436A1 (en) | 2001-06-05 | 2002-05-16 | Pharmaceutical and/or cosmetic compositions for the treatment of localised adiposities and cellulite |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040030637A KR20040030637A (ko) | 2004-04-09 |
KR100869868B1 true KR100869868B1 (ko) | 2008-11-24 |
Family
ID=11447807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037015485A KR100869868B1 (ko) | 2001-06-05 | 2002-05-16 | 국부 지방축적과 셀룰라이트의 치료를 위한 약제 및/또는화장품 조성물 |
Country Status (23)
Country | Link |
---|---|
US (1) | US7476392B2 (ko) |
EP (1) | EP1392335B1 (ko) |
JP (1) | JP4762492B2 (ko) |
KR (1) | KR100869868B1 (ko) |
CN (1) | CN100340247C (ko) |
AT (1) | ATE360427T1 (ko) |
AU (1) | AU2002304632B2 (ko) |
CA (1) | CA2449485C (ko) |
CY (1) | CY1107672T1 (ko) |
CZ (1) | CZ300576B6 (ko) |
DE (1) | DE60219782T2 (ko) |
DK (1) | DK1392335T3 (ko) |
ES (1) | ES2284870T3 (ko) |
HK (1) | HK1063295A1 (ko) |
HU (1) | HU230348B1 (ko) |
IT (1) | ITMI20011182A1 (ko) |
NO (1) | NO331789B1 (ko) |
PL (1) | PL204550B1 (ko) |
PT (1) | PT1392335E (ko) |
RU (1) | RU2291683C2 (ko) |
SI (1) | SI1392335T1 (ko) |
SK (1) | SK287612B6 (ko) |
WO (1) | WO2002098436A1 (ko) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20021280A1 (it) * | 2002-06-11 | 2003-12-11 | Carlo Ghisalberti | Metodo di trattamento anticellulite |
FR2841470B1 (fr) * | 2002-06-27 | 2006-01-13 | Pharmascience Lab | Utilisation d'isoflavones pour la preparation de compositions topiques utiles pour favoriser l'amincissement et methode de traitement cosmetique associee |
ITMI20031428A1 (it) * | 2003-07-11 | 2005-01-12 | Indena Spa | Combinazioni di agenti vasoattivi e loro uso per il trattamento di disfunzioni sessuali |
ITMI20031427A1 (it) * | 2003-07-11 | 2005-01-12 | Indena Spa | Combinazioni di agenti vasoattivi, loro uso in campo farmaceutico e cosmetico e formulazioni che li contengono |
US20050089555A1 (en) * | 2003-10-24 | 2005-04-28 | Aventis Pharma Deutschland Gmbh | Medicinal targeted local lipolysis |
DE10349979B4 (de) * | 2003-10-24 | 2006-05-18 | Sanofi-Aventis Deutschland Gmbh | Medikamentöse gezielte lokale Lipolyse |
US20050143347A1 (en) * | 2003-12-22 | 2005-06-30 | Aventis Pharma Deutschland Gmbh | Medicinal lipolysis of accumulations of fat |
KR20070086101A (ko) * | 2004-12-14 | 2007-08-27 | 메나리니 리케르체 에스.피.아. | 셀룰라이트 치료용 약제학적 조성물 |
EP1849481A4 (en) * | 2005-01-07 | 2012-11-28 | Rohto Pharma | COMPOSITION FOR TOPICAL APPLICATION |
DE102005061071A1 (de) * | 2005-12-21 | 2007-06-28 | Kneipp-Werke Kneipp-Mittel-Zentrale Gmbh & Co. Kg | Wirkstoffkombination aus Santalbinsäure oder Derivate davon und Traubenkernöl zur topischen oder dermatologischen Verwendung |
DE102007007610A1 (de) * | 2007-02-13 | 2008-08-14 | Beiersdorf Ag | Verfahren zur Steigerung der Hautelastizität und/oder eine Stärkung der Spannkraft der Haut |
ITTO20070391A1 (it) * | 2007-06-05 | 2008-12-06 | Medestea Res & Production S P | Composizione di integratore alimentare,farmaco o dispositivo medicale e suo impiego per sopprimere l'appetito, migliorare tono ed umore, con attivita antidepressiva naturale e con effetto antiastenico |
EP2419437A1 (en) * | 2009-04-17 | 2012-02-22 | Lipotec, S.A. | Peptides used in the treatment and/or care of the skin and/or hair and their use in cosmetic or pharmaceutical compositions |
KR101678254B1 (ko) * | 2009-08-12 | 2016-11-21 | 호르파그 리서치 아이피 (피와이씨) 리미티드 | 동맥경화증과 같은 심혈관 장애의 치료용 피크노제놀 또는 포도씨와 같은 프로안토시아니딘 및 병풀의 조합 |
DE102009028996A1 (de) * | 2009-08-28 | 2011-03-03 | Rovi Cosmetics International Gmbh | Kosmetische Formulierung zur Reduktion der äußeren Erscheinungsbilder von Cellulite oder Orangenhaut |
FR2962907B1 (fr) * | 2010-07-21 | 2015-05-08 | Ephyla Sas | Extrait de vegetal pour la fabrication de composition amincissante et procede de controle pour mincir mettant en oeuvre une telle composition |
BE1022293B1 (nl) | 2012-11-21 | 2016-03-14 | Wendy Angrave | Methode en composities om toxines te verwijderen uit het lichaam |
EP2968107B1 (en) | 2013-03-15 | 2019-05-08 | Mary Kay, Inc. | Cosmetic compositions and uses thereof |
CN103432045B (zh) * | 2013-09-06 | 2015-06-24 | 雅露拜尔生物科技(杭州)有限公司 | 健美瘦身组合物及健美瘦身霜 |
US20240148686A1 (en) * | 2021-02-24 | 2024-05-09 | China Pharmaceutical University | Pharmaceutical composition of forskolin-isoforskolin and pentacyclic triterpenoid compound, and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05221842A (ja) * | 1990-11-28 | 1993-08-31 | L'oreal Sa | 化粧料用痩身剤組成物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1203515B (it) * | 1987-02-26 | 1989-02-15 | Indena Spa | Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono |
IT1223290B (it) * | 1987-07-27 | 1990-09-19 | Indena Spa | Acidi poliinsaturi ad azione vasocinetica e relative formulazioni farmaceutiche e cosmetiche |
FR2684300B1 (fr) * | 1991-11-29 | 1994-03-11 | Lvmh Recherche | Composition cosmetique ou pharmaceutique, notamment dermatologique, destinee en particulier a favoriser la pigmentation de la peau ou des cheveux, contenant un extrait de ballote, et son procede de fabrication. |
JPH10182473A (ja) * | 1996-12-25 | 1998-07-07 | Lion Corp | 皮下脂肪代謝促進剤及びそれを含む外用組成物 |
ATE292469T1 (de) | 1999-09-10 | 2005-04-15 | Ceteris Holding B V Amsterdam | Ein antioxyrierungsmittel auf basis von pflanzenextrakten zur behandlung von kreislaufs- und fettsuchtproblemen |
-
2001
- 2001-06-05 IT IT2001MI001182A patent/ITMI20011182A1/it unknown
-
2002
- 2002-05-16 HU HU0400119A patent/HU230348B1/hu not_active IP Right Cessation
- 2002-05-16 US US10/477,923 patent/US7476392B2/en not_active Expired - Lifetime
- 2002-05-16 AT AT02732718T patent/ATE360427T1/de active
- 2002-05-16 PL PL366914A patent/PL204550B1/pl unknown
- 2002-05-16 RU RU2003135427/15A patent/RU2291683C2/ru not_active IP Right Cessation
- 2002-05-16 SK SK1485-2003A patent/SK287612B6/sk not_active IP Right Cessation
- 2002-05-16 SI SI200230545T patent/SI1392335T1/sl unknown
- 2002-05-16 CN CNB028112911A patent/CN100340247C/zh not_active Expired - Fee Related
- 2002-05-16 WO PCT/EP2002/005390 patent/WO2002098436A1/en active IP Right Grant
- 2002-05-16 JP JP2003501475A patent/JP4762492B2/ja not_active Expired - Fee Related
- 2002-05-16 PT PT02732718T patent/PT1392335E/pt unknown
- 2002-05-16 ES ES02732718T patent/ES2284870T3/es not_active Expired - Lifetime
- 2002-05-16 KR KR1020037015485A patent/KR100869868B1/ko not_active IP Right Cessation
- 2002-05-16 CA CA2449485A patent/CA2449485C/en not_active Expired - Fee Related
- 2002-05-16 AU AU2002304632A patent/AU2002304632B2/en not_active Ceased
- 2002-05-16 CZ CZ20033293A patent/CZ300576B6/cs not_active IP Right Cessation
- 2002-05-16 EP EP02732718A patent/EP1392335B1/en not_active Expired - Lifetime
- 2002-05-16 DE DE60219782T patent/DE60219782T2/de not_active Expired - Lifetime
- 2002-05-16 DK DK02732718T patent/DK1392335T3/da active
-
2003
- 2003-12-04 NO NO20035389A patent/NO331789B1/no not_active IP Right Cessation
-
2004
- 2004-08-13 HK HK04106092A patent/HK1063295A1/xx not_active IP Right Cessation
-
2007
- 2007-06-14 CY CY20071100788T patent/CY1107672T1/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05221842A (ja) * | 1990-11-28 | 1993-08-31 | L'oreal Sa | 化粧料用痩身剤組成物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100869868B1 (ko) | 국부 지방축적과 셀룰라이트의 치료를 위한 약제 및/또는화장품 조성물 | |
CA2028581C (en) | Compositions for treating fat deposits in humans | |
AU2002304632A1 (en) | Pharmaceutical and/or cosmetic compositions for the treatment of localised adiposities and cellulite | |
US9801809B2 (en) | Compositions including a botanical extract and methods of using the same in skin whitening and skin lightening applications | |
CN103002868A (zh) | 作为活性溶脂成分的氨基甲酸环己酯化合物 | |
EP1648403B1 (en) | Slimming cosmetic composition comprising cafestol or kahweol | |
US20070292537A1 (en) | Method and composition for reducing appearance of wrinkles | |
WO2016110276A1 (zh) | 含有黄柏酮的局部组合物及用其美白皮肤的方法 | |
KR101287052B1 (ko) | 향유 추출물을 함유하는 테스토스테론 5알파-리덕타아제저해제 | |
BE903646A (fr) | Composition pour le traitement et l'entretien de la peau | |
JPH06157277A (ja) | 皮膚化粧料 | |
JP2010150237A (ja) | セラミド産生促進剤、並びに該セラミド産生促進剤を用いた医薬品組成物、皮膚外用剤、化粧料組成物、及び化粧料 | |
JP2004256485A (ja) | 皮膚外用剤 | |
JP2000302661A (ja) | 化粧料 | |
KR20170025365A (ko) | 피부 개선용 조성물 | |
JP3553179B2 (ja) | 美白剤 | |
JP2006160655A (ja) | 筋肉活性化剤 | |
MX2007007642A (en) | Method and composition for reducing the appearance of wrinkles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121113 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20131108 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20141030 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20151028 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20161027 Year of fee payment: 9 |
|
LAPS | Lapse due to unpaid annual fee |